Our Research
Rhythm is advancing setmelanotide in a broad clinical development program that includes trials evaluating its efficacy and safety in a variety of melanocortin-4 receptor (MC4R) pathway variants.
Rhythm's research efforts include deepening the understanding of MC4R pathway-related rare genetic diseases of obesity through its DNA sequencing data streams.
To learn more about a Rhythm Pharmaceuticals clinical trial, please contact us at clinicaltrials@rhythmtx.com.